Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)
February 5, 2025 06:33 AM ESTUpdated 11:19 AM
Pharma
Manufacturing

Up­dat­ed: No­vo Nordisk sees growth slow­ing this year, plans Ca­griSe­ma fil­ing for 2026

Elizabeth Cairns

Senior biopharma journalist

No­vo Nordisk had a good 2024, but this year might be less stel­lar.

The Dan­ish com­pa­ny’s 2024 sales in­creased 26% from the year be­fore at …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Am­gen an­nounces hold on Phase 1 obe­si­ty can­di­date, pipeline cuts

GSK de­fi­ant against vac­cine chal­lenges, will pri­or­i­tize oth­er growth ar­eas

Pfiz­er says it has at least $10B avail­able for deals in 2025, with a fo­cus on pipeline

Eye­Point shares more mid-stage da­ta for ther­a­py try­ing to com­pete with Re­gen­eron's Eylea

Bris­tol My­ers, Ky­owa Kirin dis­close lay­offs

New study will try to stop Alzheimer’s decades be­fore it be­gins, us­ing ex­per­i­men­tal Eli Lil­ly drug

A service from the Financial Times